Effective post-exposure treatment of Ebola infection.

Heinz Feldmann, Steven M. Jones, Kathleen M. Daddario-DiCaprio, Joan B. Geisbert, Ute Ströher, Allen Grolla, Mike Bray, Elizabeth A. Fritz, Lisa Fernando, Friederike Feldmann, Lisa E. Hensley, Thomas Geisbert

Research output: Contribution to journalArticle

210 Citations (Scopus)

Abstract

Ebola viruses are highly lethal human pathogens that have received considerable attention in recent years due to an increasing re-emergence in Central Africa and a potential for use as a biological weapon. There is no vaccine or treatment licensed for human use. In the past, however, important advances have been made in developing preventive vaccines that are protective in animal models. In this regard, we showed that a single injection of a live-attenuated recombinant vesicular stomatitis virus vector expressing the Ebola virus glycoprotein completely protected rodents and nonhuman primates from lethal Ebola challenge. In contrast, progress in developing therapeutic interventions against Ebola virus infections has been much slower and there is clearly an urgent need to develop effective post-exposure strategies to respond to future outbreaks and acts of bioterrorism, as well as to treat laboratory exposures. Here we tested the efficacy of the vesicular stomatitis virus-based Ebola vaccine vector in post-exposure treatment in three relevant animal models. In the guinea pig and mouse models it was possible to protect 50% and 100% of the animals, respectively, following treatment as late as 24 h after lethal challenge. More important, four out of eight rhesus macaques were protected if treated 20 to 30 min following an otherwise uniformly lethal infection. Currently, this approach provides the most effective post-exposure treatment strategy for Ebola infections and is particularly suited for use in accidentally exposed individuals and in the control of secondary transmission during naturally occurring outbreaks or deliberate release.

Original languageEnglish (US)
JournalPLoS Pathogens
Volume3
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Ebola Hemorrhagic Fever
Ebolavirus
Vesicular Stomatitis
Ebola Vaccines
Disease Outbreaks
Vaccines
Animal Models
Biological Warfare Agents
Central Africa
Bioterrorism
Therapeutics
Macaca mulatta
Primates
Rodentia
Glycoproteins
Guinea Pigs
Viruses
Injections
Infection

ASJC Scopus subject areas

  • Microbiology
  • Parasitology
  • Virology
  • Immunology
  • Genetics
  • Molecular Biology

Cite this

Feldmann, H., Jones, S. M., Daddario-DiCaprio, K. M., Geisbert, J. B., Ströher, U., Grolla, A., ... Geisbert, T. (2007). Effective post-exposure treatment of Ebola infection. PLoS Pathogens, 3(1). https://doi.org/10.1371/journal.ppat.0030002

Effective post-exposure treatment of Ebola infection. / Feldmann, Heinz; Jones, Steven M.; Daddario-DiCaprio, Kathleen M.; Geisbert, Joan B.; Ströher, Ute; Grolla, Allen; Bray, Mike; Fritz, Elizabeth A.; Fernando, Lisa; Feldmann, Friederike; Hensley, Lisa E.; Geisbert, Thomas.

In: PLoS Pathogens, Vol. 3, No. 1, 01.2007.

Research output: Contribution to journalArticle

Feldmann, H, Jones, SM, Daddario-DiCaprio, KM, Geisbert, JB, Ströher, U, Grolla, A, Bray, M, Fritz, EA, Fernando, L, Feldmann, F, Hensley, LE & Geisbert, T 2007, 'Effective post-exposure treatment of Ebola infection.', PLoS Pathogens, vol. 3, no. 1. https://doi.org/10.1371/journal.ppat.0030002
Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Ströher U, Grolla A et al. Effective post-exposure treatment of Ebola infection. PLoS Pathogens. 2007 Jan;3(1). https://doi.org/10.1371/journal.ppat.0030002
Feldmann, Heinz ; Jones, Steven M. ; Daddario-DiCaprio, Kathleen M. ; Geisbert, Joan B. ; Ströher, Ute ; Grolla, Allen ; Bray, Mike ; Fritz, Elizabeth A. ; Fernando, Lisa ; Feldmann, Friederike ; Hensley, Lisa E. ; Geisbert, Thomas. / Effective post-exposure treatment of Ebola infection. In: PLoS Pathogens. 2007 ; Vol. 3, No. 1.
@article{fbc98d2dc14844f8b3a8c38800152978,
title = "Effective post-exposure treatment of Ebola infection.",
abstract = "Ebola viruses are highly lethal human pathogens that have received considerable attention in recent years due to an increasing re-emergence in Central Africa and a potential for use as a biological weapon. There is no vaccine or treatment licensed for human use. In the past, however, important advances have been made in developing preventive vaccines that are protective in animal models. In this regard, we showed that a single injection of a live-attenuated recombinant vesicular stomatitis virus vector expressing the Ebola virus glycoprotein completely protected rodents and nonhuman primates from lethal Ebola challenge. In contrast, progress in developing therapeutic interventions against Ebola virus infections has been much slower and there is clearly an urgent need to develop effective post-exposure strategies to respond to future outbreaks and acts of bioterrorism, as well as to treat laboratory exposures. Here we tested the efficacy of the vesicular stomatitis virus-based Ebola vaccine vector in post-exposure treatment in three relevant animal models. In the guinea pig and mouse models it was possible to protect 50{\%} and 100{\%} of the animals, respectively, following treatment as late as 24 h after lethal challenge. More important, four out of eight rhesus macaques were protected if treated 20 to 30 min following an otherwise uniformly lethal infection. Currently, this approach provides the most effective post-exposure treatment strategy for Ebola infections and is particularly suited for use in accidentally exposed individuals and in the control of secondary transmission during naturally occurring outbreaks or deliberate release.",
author = "Heinz Feldmann and Jones, {Steven M.} and Daddario-DiCaprio, {Kathleen M.} and Geisbert, {Joan B.} and Ute Str{\"o}her and Allen Grolla and Mike Bray and Fritz, {Elizabeth A.} and Lisa Fernando and Friederike Feldmann and Hensley, {Lisa E.} and Thomas Geisbert",
year = "2007",
month = "1",
doi = "10.1371/journal.ppat.0030002",
language = "English (US)",
volume = "3",
journal = "PLoS Pathogens",
issn = "1553-7366",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - Effective post-exposure treatment of Ebola infection.

AU - Feldmann, Heinz

AU - Jones, Steven M.

AU - Daddario-DiCaprio, Kathleen M.

AU - Geisbert, Joan B.

AU - Ströher, Ute

AU - Grolla, Allen

AU - Bray, Mike

AU - Fritz, Elizabeth A.

AU - Fernando, Lisa

AU - Feldmann, Friederike

AU - Hensley, Lisa E.

AU - Geisbert, Thomas

PY - 2007/1

Y1 - 2007/1

N2 - Ebola viruses are highly lethal human pathogens that have received considerable attention in recent years due to an increasing re-emergence in Central Africa and a potential for use as a biological weapon. There is no vaccine or treatment licensed for human use. In the past, however, important advances have been made in developing preventive vaccines that are protective in animal models. In this regard, we showed that a single injection of a live-attenuated recombinant vesicular stomatitis virus vector expressing the Ebola virus glycoprotein completely protected rodents and nonhuman primates from lethal Ebola challenge. In contrast, progress in developing therapeutic interventions against Ebola virus infections has been much slower and there is clearly an urgent need to develop effective post-exposure strategies to respond to future outbreaks and acts of bioterrorism, as well as to treat laboratory exposures. Here we tested the efficacy of the vesicular stomatitis virus-based Ebola vaccine vector in post-exposure treatment in three relevant animal models. In the guinea pig and mouse models it was possible to protect 50% and 100% of the animals, respectively, following treatment as late as 24 h after lethal challenge. More important, four out of eight rhesus macaques were protected if treated 20 to 30 min following an otherwise uniformly lethal infection. Currently, this approach provides the most effective post-exposure treatment strategy for Ebola infections and is particularly suited for use in accidentally exposed individuals and in the control of secondary transmission during naturally occurring outbreaks or deliberate release.

AB - Ebola viruses are highly lethal human pathogens that have received considerable attention in recent years due to an increasing re-emergence in Central Africa and a potential for use as a biological weapon. There is no vaccine or treatment licensed for human use. In the past, however, important advances have been made in developing preventive vaccines that are protective in animal models. In this regard, we showed that a single injection of a live-attenuated recombinant vesicular stomatitis virus vector expressing the Ebola virus glycoprotein completely protected rodents and nonhuman primates from lethal Ebola challenge. In contrast, progress in developing therapeutic interventions against Ebola virus infections has been much slower and there is clearly an urgent need to develop effective post-exposure strategies to respond to future outbreaks and acts of bioterrorism, as well as to treat laboratory exposures. Here we tested the efficacy of the vesicular stomatitis virus-based Ebola vaccine vector in post-exposure treatment in three relevant animal models. In the guinea pig and mouse models it was possible to protect 50% and 100% of the animals, respectively, following treatment as late as 24 h after lethal challenge. More important, four out of eight rhesus macaques were protected if treated 20 to 30 min following an otherwise uniformly lethal infection. Currently, this approach provides the most effective post-exposure treatment strategy for Ebola infections and is particularly suited for use in accidentally exposed individuals and in the control of secondary transmission during naturally occurring outbreaks or deliberate release.

UR - http://www.scopus.com/inward/record.url?scp=34250354033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250354033&partnerID=8YFLogxK

U2 - 10.1371/journal.ppat.0030002

DO - 10.1371/journal.ppat.0030002

M3 - Article

C2 - 17238284

AN - SCOPUS:33846500073

VL - 3

JO - PLoS Pathogens

JF - PLoS Pathogens

SN - 1553-7366

IS - 1

ER -